Rana Nikzad

Medicine · Health Sciences

10h-index481citations35works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(21), Cancer, Hypoxia, and Metabolism(11), Immune Cell Function and Interaction(6), Protein Degradation and Inhibitors(4), Cancer-related Molecular Pathways(3)

Publications35 total

Supplementary Figure 3 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 4 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 4 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 6 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Data from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 7 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 7 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Data from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Information from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 6 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 1 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 5 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 5 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 2 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 2 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 9 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 3 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Information from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Silke Paust(30), Kevin Aviles-Padilla(25), Myrthala Moreno‐Smith(23), Anna Lakoma(23), Zaowen Chen(23), Kathleen A. Scorsone(23), Linda Schild(23), Yankai Zhang(23), Rikhia Chakraborty(23), Jan J. Molenaar(23), Sanjeev A. Vasudevan(23), Vivien Sheehan(23), Eugene S. Kim(23), Jason M. Shohet(23), Eveline Barbieri(23), Ling Tao(22), Shawn Abeynaike(5), Duy T. Le(3), Reesha R. Patel(3), Amanda J. Roberts(3)